Relay Therapeutics (RLAY) Expected to Announce Quarterly Earnings on Wednesday

Relay Therapeutics (NASDAQ:RLAY) will likely be releasing its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect Relay Therapeutics to post earnings of ($0.38) per share for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:00 PM ET.

Relay Therapeutics Price Performance

RLAY opened at $8.94 on Tuesday. Relay Therapeutics has a fifty-two week low of $1.77 and a fifty-two week high of $9.54. The firm has a market capitalization of $1.55 billion, a P/E ratio of -5.11 and a beta of 1.59. The company’s 50-day moving average is $8.27 and its 200 day moving average is $6.59.

Insider Transactions at Relay Therapeutics

In other news, insider Donald A. Bergstrom sold 18,895 shares of Relay Therapeutics stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $7.62, for a total value of $143,979.90. Following the completion of the transaction, the insider owned 422,733 shares in the company, valued at $3,221,225.46. This trade represents a 4.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Thomas Catinazzo sold 13,820 shares of the business’s stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $7.62, for a total transaction of $105,308.40. Following the completion of the sale, the chief financial officer directly owned 250,996 shares in the company, valued at approximately $1,912,589.52. This trade represents a 5.22% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 93,302 shares of company stock valued at $724,355. 4.32% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of RLAY. Smartleaf Asset Management LLC raised its holdings in Relay Therapeutics by 288.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company’s stock valued at $37,000 after acquiring an additional 3,287 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in shares of Relay Therapeutics in the fourth quarter valued at $46,000. Captrust Financial Advisors bought a new stake in shares of Relay Therapeutics during the 2nd quarter valued at $49,000. Cerity Partners LLC bought a new stake in shares of Relay Therapeutics during the 2nd quarter valued at $51,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in Relay Therapeutics during the 1st quarter worth about $53,000. 96.98% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Friday, January 9th. Wells Fargo & Company raised Relay Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $6.00 to $13.00 in a research report on Friday, December 12th. Finally, Oppenheimer upgraded Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 target price on the stock in a research note on Monday, January 26th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Relay Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $16.57.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.